Kymab secures $100m and two new Chinese backers

By Gareth Macdonald contact

- Last updated on GMT

Cytovance facility in Oklahoma City, US likely to play role in production of Kymab mAbs (source Google images)
Cytovance facility in Oklahoma City, US likely to play role in production of Kymab mAbs (source Google images)

Related tags: China, Monoclonal antibodies

Antibody developer Kymab has secured $100m from existing backers and new China-based investors Hepalink and ORI Healthcare Fund.

Kymab will use the funds to pay for development of its therapeutic monoclonal antibodies (mAb) the first of which, the Graft-versus-host disease (GvHD) candidate KY1005, is due to enter clinical trials in 2017.

Hepalink is a Shenzhen, China-based supplier of heparin sodium active pharmaceutical ingredient (API). It entered the large molecule sector last year​ when it acquired Cytovance Biologics for $206m (€183m).

Through Cytovance, Hepalink operates a mammalian and microbial cell development and manufacturing facility in Oklahoma City, US.

Kymab CEO, David Chiswell told us “Hepalink has a biological strategy and are actively developing antibodies for the Chinese market in addition they have antibody manufacturing facilities in the US. 

“We hope to collaborate together in the future either through using their manufacturing facilities in the US or developing some of our antibodies in China. Ori Fund have a large network in China and we will work with them to ​leverage their expertise.”

China, where both Hepalink and ORI are based, is a key market for UK-based Kymab according to Chiswell.

“Since Kymab was established, we have been targeting the Chinese market we have a network of contacts in the region who understand and appreciate the power of our platform​.”

Related news

Show more

Related products

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Fill-Finish Biologics

Fill-Finish Biologics

Curia | 16-May-2022 | Technical / White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...

Related suppliers

Follow us

Products

View more

Webinars